Table 3

Effectiveness of six different switching strategies (first TNFi→second TNFi) based on ΔDAS28 after 6 months, % of patients with low disease activity or remission at 6 months and % of patients achieving ΔDAS28 of at least 1.2 at 6 months

First TNFi→second TNFi
INF→ETA
N=242
INF→ADA
N=101
ETA→INF
N=58
ETA→ADA
N=329
ADA→INF
N=16
ADA→ETA
N=206
DAS28 baseline*5.3±1.4
(197)
4.7±1.4
(78)
5.1±1.3
(45)
4.7±1.4
(257)
4.8±1.5
(14)
4.9±1.3
(175)
DAS28 6 months**3.8±1.5
(180)
3.3±1.5
(64)
3.7±1.5
(38)
4.0±1.5
(225)
3.6±1.5
(10)
3.9±1.5
(141)
ΔDAS28 6 months***−1.6±1.5
(150)
−1.2±1.6
(48)
−1.2±1.6
(30)
−0.7±1.5
(196)
−0.6±0.9
(8)
−1.2±1.6
(125)
% Low disease activity or remission at 6 months38.0%
(184)
47.0%
(66)
31.6%
(38)
31.6% [228)54.5%
(11)
29.1% [148)
% With DAS28 improvement ≥1.2 at 6 months58.7%
(150)
45.8%
(48)
56.7%
(30)
33.2%
(196)
12.5%
(8)
50.4%
(125)
  • *p<0.0001 INF→ETA vs ETA→ADA, p=0.04 INF→ETA vs INF→ADA.

  • **p=0.01 INF→ADA vs ETA→ADA.

  • ***p<0.0001 INF→ETA vs ETA→ADA (remained significant after correction for baseline DAS28, p=0.004).

  • ADA, adalimumab; DAS28, disease activity score based on 28-joint status; ΔDAS28, DAS28 change; ETA, etanercept; INF, infliximab; TNFi, tumour necrosis factor inhibitor.